NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

Shares of Melinta Therapeutics reverse split on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.

Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.14) by $0.24. The biotechnology company earned $12.02 million during the quarter, compared to analysts' expectations of $12.06 million. Melinta Therapeutics had a negative return on equity of 68.68% and a negative net margin of 202.31%. View Melinta Therapeutics' Earnings History.

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Melinta Therapeutics.

7 equities research analysts have issued 12 month price objectives for Melinta Therapeutics' shares. Their predictions range from $8.00 to $15.00. On average, they anticipate Melinta Therapeutics' stock price to reach $12.5833 in the next twelve months. This suggests a possible upside of 92.4% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.

Media headlines about MLNT stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Melinta Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Melinta Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,178,376 shares, a decrease of 28.3% from the January 15th total of 1,644,462 shares. Based on an average trading volume of 397,029 shares, the short-interest ratio is presently 3.0 days. Currently, 3.3% of the shares of the stock are sold short. View Melinta Therapeutics' Current Options Chain.

Some companies that are related to Melinta Therapeutics include Neptune Wellness Solutions (NEPT), Catalyst Pharmaceuticals (CPRX), Kala Pharmaceuticals (KALA), Constellation Pharmaceuticals (CNST), Verrica Pharmaceuticals (VRCA), Emisphere Technologies (EMIS), BIOFRONTERA AG/ADR (BFRA), Immune Design (IMDZ), Kadmon (KDMN), Geron (GERN), TapImmune (MRKR), Aclaris Therapeutics (ACRS), Merus (MRUS), Axsome Therapeutics (AXSM) and Synlogic (SYBX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Gilead Sciences (GILD), Celgene (CELG), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Micron Technology (MU), Portola Pharmaceuticals (PTLA), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD) and TransEnterix (TRXC).

Melinta Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.52%), First Manhattan Co. (1.69%), Dimensional Fund Advisors LP (1.38%), Millennium Management LLC (1.07%), Fosun International Ltd (0.88%) and Geode Capital Management LLC (0.75%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

MLNT stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Millennium Management LLC. View Insider Buying and Selling for Melinta Therapeutics.

MLNT stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Assenagon Asset Management S.A., Boenning & Scattergood Inc., BlackRock Inc., Condor Capital Management, Dimensional Fund Advisors LP and Rhumbline Advisers. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MLNT stock can currently be purchased for approximately $6.54.

Melinta Therapeutics has a market capitalization of $366.37 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

The official website for Melinta Therapeutics is http://melinta.com.

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]